Evidence map›Paper›PMID 41487559›Full record

ArticleJournal of hepatocellular carcinoma2025

Nationwide Prevalence of Hepatocellular Carcinoma in Saudi Arabia: A Population-Based Analysis for 2021.

Edward B De Vol, Shouki Bazarbashi, Mohamed Aseafan, Haya Sulaiman Aleid, Afnan Alnajem, Saleh A Alqahtani, Ali Alqahtani

Abstract read
In one paragraph

Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Edward B De VolDepartment of Biostatistics, Epidemiology and Scientific Computing, King Faisal Specialist Hospital and Research Center, Riyadh, Riyadh Province, Saudi Arabia.
Shouki BazarbashiDepartment of Medical Oncology, Cancer Centre of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Riyadh Province, Saudi Arabia.ORCID 0000-0002-8913-8158
Mohamed AseafanDepartment of Internal Medicine, Security Forces Hospital, Riyadh, Riyadh Province, Saudi Arabia.ORCID 0000-0001-9993-9664
Haya Sulaiman AleidAssistant Agency for Hospital Services, Ministry of Health, Riyadh, Riyadh Province, Saudi Arabia.
Afnan AlnajemDepartment of Biostatistics, Epidemiology and Scientific Computing, King Faisal Specialist Hospital and Research Center, Riyadh, Riyadh Province, Saudi Arabia.ORCID 0000-0002-3483-6696
Saleh A AlqahtaniOrgan Transplant Centre of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Riyadh Province, Saudi Arabia.ORCID 0000-0003-2017-3526
Ali AlqahtaniDepartment of Medical Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Riyadh Province, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Liver cancer, predominantly hepatocellular carcinoma (HCC), represents a significant health burden in Saudi Arabia, ranking as the 8 Patients and Methods: A population-based prevalence estimation study was conducted using incident HCC cases reported to the SCR (2005-2017), population census data (2005-2020), and published national survival data. The study population comprised all newly diagnosed HCC cases reported during the study period. Prevalence was calculated by multiplying incident cases from each diagnosis cohort by their corresponding age- and gender-specific survival probabilities to estimate the number of HCC survivors alive in 2021, divided by the population at risk. Monte Carlo simulation with binomial distribution (n = incident cases; p = survival probability) was performed 1000 times to generate a distribution of prevalent cases, with 2.5th and 97.5th percentiles defining 95% confidence intervals. Age- and gender-specific prevalence rates were standardized to the WHO 2000-2025 World Standard Population using direct standardization for international comparability. Results: Between 2005 and 2020, 6743 HCC cases were newly diagnosed and reported to the SCR, comprising 4685 males (69.5%) and 2058 females (30.5%). By the end of 2020, the estimated number of male HCC survivors was 637.3 (95% CI: 612.8-663.2), while females numbered 496.9 (95% CI: 474.1-521.8). In 2021, the age-standardized prevalence rate of HCC was 8.62 per 100,000 population for males (95% CI: 8.28-8.98) and 6.36 per 100,000 for females (95% CI: 6.08-6.67), with an overall combined age-standardized rate of 7.49 per 100,000 (95% CI: 7.25-7.76). HCC prevalence increased progressively with age, with the highest proportion of diagnosed cases occurring in individuals aged 75 years and above (males: n=1315; females: n=420). Younger cohorts diagnosed after 2015 showed markedly improved survival rates compared to those diagnosed in 2005, reflecting advances in treatment modalities. Conclusion: This study provides a comprehensive population-based estimate of HCC prevalence in Saudi Arabia, demonstrating substantial gender and age disparities in disease burden. The predominance of HCC in males and elderly populations underscores the need for targeted epidemiological research to identify modifiable risk factors, particularly given the markedly lower prevalence of alcohol-related liver disease compared to global HCC endemic regions. The methodological framework utilizing integration of incidence, population-based survival data, and WHO standardization provides a replicable model for disease burden estimation in countries with limited prevalence survey infrastructure. Future research should focus on disease etiology, including the role of chronic hepatitis B, chronic hepatitis C, metabolic-associated steatotic liver disease, and the evolving patterns of liver disease in Saudi Arabia.

Indexed as

disease burdenepidemiologyhepatocellular carcinomapopulation-based registryprevalenceSaudi ArabiaWHO standardization

Identifiers

PMID41487559
PMCPMC12764305

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.